Chronic liver diseases (CLD) such as hepatitis B and C virus infection, alcoholic liver disease, and non-alcoholic steatohepatitis are associated with hepatic cellular necrosis, continual inflammation, and hepatic fibrosis. The induced microenvironment triggers the activation of liver-resident progenitor cells (LPCs) while hepatocyte replication is inhibited. In the early injury stages, LPCs regenerate the liver by proliferation, migration to sites of injury, and differentiation into functional biliary epithelial cells or hepatocytes. However, when this process becomes dysregulated, wound healing can progress to pathological fibrosis, cirrhosis, and eventually hepatocellular carcinoma. The other key mediators in the pathogenesis of progressive CLD are fibrosis-driving, activated hepatic stellate cells (HSCs) that usually proliferate in very close spatial association with LPCs. Recent studies from our group and others have suggested the potential for cytokine and chemokine cross-talk between LPCs and HSCs, which is mainly driven by the tumor necrosis factor (TNF) family members, TNF-like weak inducer of apoptosis (TWEAK) and lymphotoxin-β, potentially dictating the pathological outcomes of chronic liver injury.

Keywords: liver progenitor cells, hepatic stellate cells, regeneration, fibrosis, cancer, TWEAK, LTβ, NFκB

INTRODUCTION

The liver possesses an extraordinary ability to orchestrate hepatocyte-mediated regeneration from acute injuries such as tissue resection or hepatic necrosis. However, hepatocyte proliferation is impaired or ablated by severe and chronic injury, dictating the need for an alternative liver regeneration pathway. Through a complex network of chemical and cellular mediators, the liver regenerates via the activation of a progenitor cell compartment, which retains proliferative and restorative capacities under severe injury conditions. Early chronic liver disease is typified by hepatocellular necrosis, hepatic inflammation, and hepatic fibrosis. The induced microenvironment triggers the activation of resident hepatic stellate cells (HSCs). During chronic liver disease, quiescent HSCs are "activated" by inflammatory cytokines and begin to express α-smooth muscle actin (αSMA), signifying their transition to a myofibroblastic phenotype (11). Following this transition, activated HSCs drive fibrosis by depositing extracellular matrix (ECM) proteins, which inhibits matrix metalloproteinases (MMPs), which function to degrade ECM proteins (12). Activated HSCs further reinforce regenerative and repair responses by expressing chemotactic factors such as intercellular adhesion molecule 1 (ICAM-1) and regulated upon activation, normal T-cell expressed, and secreted (RANTES), which attract additional inflammatory and progenitor cells to the site of injury (13). If the hepatic insult is resolved, LPCs mature to replace the lost epithelial cell types, hepatocytes, and/or cholangiocytes, depending on the underlying pathology. At the same time fibrosis recedes restoring structural and functional

TWEAK and LTβ signaling during chronic liver disease

Benjamin J. Dwyer 1, John K. Olynky 1,2,3,4, Grant A. Ramm 5,6 and Janina E. E. Timitz-Parker 1,2 *

1 School of Biomedical Sciences, CHIIRI Biosciences Research Precinct, Curtin University, Bentley, WA, Australia
2 School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA, Australia
3 Department of Gastroenterology, Fremantle Hospital, Fremantle, WA, Australia
4 Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia
5 Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
6 QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

*Correspondence:
Janina E. E. Timitz-Parker, Liver Disease and Regeneration Laboratory, School of Biomedical Sciences, CHIIRI Biosciences Research Precinct, Curtin University, Kent Street, Bentley, WA 6102, Australia
E-mail: n.timitz-parker@curtin.edu.au

Edited by:
Linda C. Burkly, Biogen Idec, Inc., USA
Reviewed by:
Urs Christen, Klinikum der Goethe Universität Frankfurt, Germany
Takayuki Yoshimoto, Tokyo Medical University, Japan
Vury Popov, Beth Israel Deaconess Medical Center, USA

The regenerative response consists of the "ductular reaction" (DR), in which bile ductules and liver progenitor cells (LPCs) proliferate from the Canals of Hering, the interface between the hepatocyte canaliculi and the biliary tree (1), resulting in biliary hyperplasia and the appearance of intermediate hepatocytes (2). Recent lineage-labeling studies have demonstrated that LPCs arise from a population of Sox9-expressing ductal cells that are activated to proliferate and differentiate into hepatocytes under certain chronic liver injury conditions (3, 4). This expansion is initiated and maintained by inflammatory cell-derived stimuli such as tumor necrosis factor (TNF) (5, 6) and interferon (IFN)-γ (7). Importantly, IFNγ has been shown to promote LPC expansion and inhibit proliferation of hepatocytes in concert with TNF stimulation (7). Additionally, transforming growth factor (TGF)-β suppresses liver epithelial cell proliferation. However, LPCs are significantly less sensitive to TGFβ-mediated growth inhibition during chronic liver injury and in vitro (8). In addition to stimuli from inflammatory cells, dying hepatocytes release hedgehog ligand (9), which has recently been shown to signal via the canonical Smoothened-dependent signaling cascade in primary cilium-positive LPCs, promoting their proliferation (10). Thus, the consequence of chronic hepatocyte injury and the subsequent inflammatory response is a liver microenvironment, which supports LPC expansion, while disabling hepatocyte-mediated regeneration.

LPC expansion occurs almost synchronously with fibrogenic wound healing, which is primarily driven by the action of hepatic stellate cells (HSCs). During chronic liver disease, quiescent HSCs are "activated" by inflammatory cytokines and begin to express α-smooth muscle actin (αSMA), signifying their transition to a myofibroblastic phenotype (11). Following this transition, activated HSCs drive fibrosis by depositing extracellular matrix (ECM) proteins, which inhibits matrix metalloproteinases (MMPs), which function to degrade ECM proteins (12). Activated HSCs further reinforce regenerative and repair responses by expressing chemotactic factors such as intercellular adhesion molecule 1 (ICAM-1) and regulated upon activation, normal T-cell expressed, and secreted (RANTES), which attract additional inflammatory and progenitor cells to the site of injury (13). If the hepatic insult is resolved, LPCs mature to replace the lost epithelial cell types, hepatocytes, and/or cholangiocytes, depending on the underlying pathology. At the same time fibrosis recedes restoring structural and functional
integrity of the liver. However, if injury persists, the regenerative and wound healing processes spiral out of control and become pathological. Chronic stimulation of HSCs results in fibrosis from excessive matrix deposition. With further impaired regeneration, this may progress to cirrhosis and liver failure. Furthermore, the prolonged stimulation of LPCs by pro-proliferative/survival cytokines from inflammatory cells generates a niche favoring the accumulation of genetic and epigenetic alterations, which can lead to the malignant transformation of LPCs and ultimately the formation of hepatocellular carcinoma (HCC).

A combination of association studies in patients and pathway manipulation experiments in rodents implicate LPCs as key regulatory cells in progressive chronic liver injury. LPCs are observed in many diseases with a predisposition to HCC, including chronic hepatitis B (HBV) and C virus (HCV) infection (14, 15), non-alcoholic fatty liver disease (16), alcoholic liver disease, and genetic hemochromatosis (14). Importantly, the numbers of LPCs increase as liver fibrosis progresses to cirrhosis, regardless of the underlying liver pathology (14, 17). Since LPCs proliferate at various stages of human liver tumorigenesis, ranging from preneoplastic lesions (18) to well-developed HCCs (19–21), they have been suggested as causative players during tumor development and maintenance. Supporting evidence comes from murine intervention studies where selective inhibition of c-kit+ LPCs by imatinib mesylate resulted in reduced tumor formation (6). These studies suggest that LPCs either represent direct cellular precursors of HCC or they crucially influence disease development by regulating other contributing cells such as fibrosis-driving HSCs. Either way they represent ideal chemotherapeutic targets for HCC prevention strategies in chronic liver injury.

The processes of inflammation, fibrosis, and LPC induction are tightly regulated and occur in close spatial association (Figure 1), suggesting the potential for cellular communication (Figure 2). Cross-talk between the hepatic wound healing and regenerative responses occurs via several factors including ECM proteins, growth factors, and cytokines, particularly of the TNF superfamily. In this review, we will discuss the role of two TNF superfamily members, lymphotoxin-β (LTβ), and TNF-like weak inducer of apoptosis (TWEAK), in regulating liver regeneration and wound healing.

**TWEAK/FN14 SIGNALING**

**TWEAK/FN14 SIGNALING INDUCES LPC PROLIFERATION VIA NFκB ACTIVATION**

TWEAK ligand was first identified as a novel cell-associated and secreted factor with TNF family homology, which induced cytotoxicity in the human adenocarcinoma cell line HT29 in combination with IFNγ treatment (28). TWEAK interacts with target cells via its receptor, fibroblast growth factor-inducible 14 (F14) (29), which is highly homologous in mouse and human tissues, and is upregulated in HCC lines and tissues (30). Biologically, TWEAK has been shown to regulate numerous cellular processes including proliferation, differentiation, migration, and cell survival and has also been described as a pro-angiogenic and inflammatory cells. The spatial proximity of all three cell types suggests the potential for cellular cross-talk and co-regulation of the inflammatory, fibrogenic, and progenitor cell responses. Nuclei are stained with DAPI (blue). Scale bars represent 50 μm.
pro-inflammatory factor (31). In chronic liver injury and repair, the principal function of TWEAK appears to initiate ductal proliferation and LPC expansion via activation of NFκB signaling. Ductal hyperplasia is observed in livers of mice overexpressing TWEAK under the control of the liver-specific α1-antitrypsin promoter, demonstrating the ability of TWEAK signaling, in isolation, to initiate ductal expansion (32). Conversely, ductal cell expansion is mitigated after pharmacological blocking of TWEAK signaling, as well as in Fn14-knockout mice subjected to either 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) or choline-deficient, ethionine-supplemented (CDE)-induced chronic liver injury (22, 32). Furthermore, macrophages and natural killer cells have been shown to be the primary producers of TWEAK ligand in chronic liver injury, providing an important link between the inflammatory response and TWEAK-mediated ductal expansion (33). In the CDE model, TWEAK-producing macrophages have been observed in close association with expanding ductal cells (33), suggesting a mechanism whereby focal points of inflammatory cell signals via the TWEAK/Fn14 pathway to promote LPC expansion. Accordingly, transplantation of bone marrow-derived macrophages into normal liver stimulates a TWEAK-dependent response in LPCs and biliary cells, demonstrating a primary role of macrophage-generated TWEAK in initiating the DR (23). Previous studies indicate that this effect is mediated via TWEAK-induced activation of NFκB signaling (22).

The NFκB family comprises five monomers, which interact via N-terminal Rel homology domain (RHD) polypeptides. These monomers, RelA, RelB, cRel, p50, and p52, interact to form an active NFκB homo- or heterodimer and translocate to the nucleus to activate transcription of genes involved in numerous biological processes including, but not limited to, inflammation, proliferation, and cell survival (34). Regulation of nuclear localization occurs by sequestering of NFκB dimers through binding with inhibitory proteins (IκBs). Inhibition is released through phosphorylation and subsequent proteolytic degradation of IκB. Phosphorylation of IκB is initiated by binding of extracellular mediators to their receptors, which lead to activation of IκB-kinase (IKK) via NFκB essential modulator (NEMO)-dependent (canonical) or independent (non-canonical) mechanisms (35). NFκB plays a vital role in all aspects of chronic liver diseases (CLD), acting as...
a transducer of cytokine-mediated signals promoting inflammation and fibrosis (36), particularly in the survival and activation of HSCs (37, 38). NFκB signaling is activated upon TNF treatment of LPCs, promoting its mitogenic effects (39), and also regulates IL-6/TNF-mediated upregulation of LTβ in LPCs (40, 41).

TWEAK has been shown to activate NFκB via canonical (42) and non-canonical mechanisms (43). Accordingly, strong cytoplasmic and nuclear NFκB is observed in proliferating pan cytokeratin-expressing cholangiocytes and LPCs following recombiant TWEAK administration in CDE-injured mice (22). In vitro studies in the LPC lines BMOL and BMOL-TAT demonstrated dose-dependent proliferation following TWEAK stimulation. Mitogenesis was inhibited by transfection with siRNA targeting the NFκB p50 subunit, confirming the pro-proliferative effect of TWEAK in LPCs is NFκB-dependent (22). The ability of TWEAK to promote proliferation and self-renewal of LPCs appears to be vital in allowing LPCs to survive and thrive in the chronic liver injury setting. Interestingly, this modulation also affects the dynamics of hepatic fibrosis and inflammation.

**TWEAK AS A REGULATOR OF FIBROGENESIS**

Assessing the cellular players involved in TWEAK signaling provides unique insights into its versatile role in establishing a niche conducive to wound healing, regeneration as well as carcinogenesis. In addition to stimulating ductal/LPC expansion, one of the therapeutically interesting consequences of altering TWEAK signaling in chronic liver injury is the co-modulation of liver fibrosis. Experiments utilizing TWEAK pathway knockout mice and exogenous TWEAK stimulation/inhibition have shown a positive correlation between LPC proliferation and the fibrogenic response to chronic liver injury. Collagen deposition and the expression of TIMPs are reduced in Fn14-knockout mice on the CDE diet to chronic liver injury. Collagen deposition and the expression of TIMPs are reduced in Fn14-knockout mice on the CDE diet (22). In vitro studies in the LPC lines BMOL and BMOL-TAT demonstrated dose-dependent proliferation following TWEAK stimulation. Mitogenesis was inhibited by transfection with siRNA targeting the NFκB p50 subunit, confirming the pro-proliferative effect of TWEAK in LPCs is NFκB-dependent (22). The ability of TWEAK to promote proliferation and self-renewal of LPCs appears to be vital in allowing LPCs to survive and thrive in the chronic liver injury setting. Interestingly, this modulation also affects the dynamics of hepatic fibrosis and inflammation.

**LPC/HSC CROSS-TALK VIA LTβ SIGNALING**

In an effort to understand the opposing roles of LPCs and HSCs in controlling regeneration and wound healing versus fibrogenesis progression and carcinogenesis, pathways involved in LPC/HSC cross-talk are currently under investigation. As we have discussed, modulating the LPC response via TWEAK signaling affects the dynamics of liver fibrosis mediated by HSCs. Additionally, Boulter et al. demonstrated regulation of LPC differentiation by activated HSCs through expression of the Notch ligand Jagged 1 and Notch-dependent biliary specification in adjacent LPCs (24). Conversely, expression of MCP-1 by cholangiocytes within hyperplastic or mature bile ducts was shown to drive HSC/myofibroblast chemotaxis in chronic cholestatic liver disease (25). These studies demonstrate the clear interactions of LPCs and HSCs during progressive chronic liver injury. Thus, interventions targeting pathways modulating LPC/HSC interactions might be of therapeutic benefit in patients with chronic liver disease. One such novel target is the TNF family member LTβ, which was recently discovered as a key regulator of LPC/HSC cross-talk, facilitated by NFκB-dependent downstream signaling (13).

LTβ is a type II transmembrane protein that signals as a cell surface-anchored heterotrimer with LTα (i.e., LTα2β1 or predominately LTα1β2) (46). LTβ levels are increased in various animal chronic liver injury models including bile duct ligation (47) and CDE-induced injury (48, 49) and its expression correlates with the severity of fibrosis in chronic HCV infection in humans (50). It has been demonstrated on the surface of cells of the lymphocytic lineage, including activated B and T cells as well as natural killer cells (51) but interestingly also on small portal hepatocytes and proliferating LPCs during chronic liver injury (50). In our CDE injury model, these LTβ+ LPCs are observed in close proximity to activated HSCs, which express the LTβ receptor (LTβR). In vitro studies revealed that upon receptor binding, LTβ initiates a NFκB-dependent signaling cascade in HSCs that...
results in expression of chemotaxis-associated mediators ICAM-1 and RANTES, which in turn recruit RANTES receptor (C–C chemokine receptor type 5, CCR5)-positive LPCs (13). Hence this paracrine cytokine/chemokine cross-talk has the capacity to facilitate LPC and HSC migration through the liver parenchyma to sites of injury in addition to promoting wound healing by recruitment of new leukocytes, LPCs and HSCs. The LTβ signaling pathway also plays a role in fibrogenesis, since chronically injured LTβR knockout mice show reduced numbers of αSMA+ HSCs and decreased collagen deposition as evidenced by reduced Sirius Red staining (13). Concurrently, numbers of A6+ and muscle pyruvate kinase 2 (M2P2K)+ LPCs are reduced (48), which once again suggests the co-regulation of the fibrogenic and the progenitor cell response in chronic liver injury. The significance of the LTβ pathway in liver disease and hepatocarcinogenesis was highlighted by Haybacek et al. who analyzed tg1223 mice, which overexpress lymphotoxin β (LTβ) and developed a risk of liver injury, and showed that sustained expression leads to chronic hepatitis and eventually to HCC. To confirm results, LTβ overexpression was neutralized by pharmacological blocking of LTβR, which drastically reduced liver injury and prevented HCC formation (19). Hence, suppression of this pathway might be beneficial in liver diseases with a chronic overexpression of cytokines that signal through LTβR, including LTα and LTβ or LTβ-related inducible ligand competing for glycoprotein D binding to herpes virus entry mediator on T cells (LIGHT), such as seen in chronic HBV or HCV infection.

**THERAPEUTIC POTENTIAL AND FUTURE DIRECTIONS**

In the Western world, chronic liver injury is ever increasing in prevalence. A variety of etiologies including chronic HBV/HCV infection, and non-alcoholic fatty liver disease can cause fibrosis and, subsequently, cirrhosis and HCC. The World Health Organization ranks CLD as the ninth commonest global cause of death with end organ failure as a result of cirrhosis and HCC, accounting for half the mortality each (52). Most HCC cases arise in the setting of established cirrhosis, with a median survival of 6–16 months, if untreated (53). At present, a range of primary treatment options including antiviral therapy and weight reduction strategies are variably effective in these conditions. Unfortunately, a significant number of patients still progress to end-stage liver disease and many require orthotopic liver transplantation. However, limited availability of donor organs and religious and/or economic reasons may restrict access to transplantation surgery. Prolonged waiting times for donor organs often result in disease progression and death of patients with initially treatable disease. Thus, the development of new therapeutic strategies for the prevention or treatment of hepatic fibrosis and its sequelae of cirrhosis and HCC are urgently required.

The carcinogenic and fibrogenic processes are amenable to manipulation by agents, which interfere with these processes, however to date approaches have been limited, and new targeted therapies such as tyrosine kinase inhibitors have not significantly improved survival (54, 55). Identification of new cellular targets for preventative therapies that minimize fibrosis or carcinogenesis represent the future for advancement of therapy, and knowledge of cross-talk and signaling pathways such as those defined here are critical for such advancement. The key will be balancing beneficial effects on reduced fibrosis and carcinogenesis against detrimental effects consequential to impaired replacement of healthy hepatocytes or cholangiocytes, as can be seen following IFN-based therapies for chronic viral hepatitis (56).

**SUMMARY**

The liver responds to chronic injury by initiating an inflammatory response, which enables the dual action of resolving injury, through the activation of fibrosis, and regeneration of injured tissue comprising the activation and differentiation of LPCs. These processes are inextricably linked and act in concert to reinforce and progress the chronic injury response until such a time that injury abates. Since these processes are linked, affecting the biology of one necessarily affects the dynamics of the whole system. As we have discussed in this review, TWEAK/Fn14 signaling plays a primary role in regulating LPC expansion and in doing so, affects both the inflammatory and wound healing responses of the liver through cellular cross-talk. Through interactions between LPCs and the immune system, TWEAK modulation of LPC numbers may act to enhance the inflammatory response at the site of regeneration, reinforcing LPC expansion. Likewise, LPC interactions with HSCs via LTβ signaling may also promote recruitment of leukocytes to the site of injury, amplifying the fibrogenic response of the liver. Accordingly, TWEAK signaling may be an important “valve” with which we might modulate the landscape of chronic liver injury. Therefore, we propose that therapies targeting TWEAK signaling in chronic liver injury may be useful for reducing the severity of fibrosis through its dual action on the inflammatory and HSC compartments via LPCs. In doing so, it may be possible to diminish progression to cirrhosis and liver failure, as well as limiting the pro-tumorigenic environment existing in the regenerative niche supporting LPCs.

**ACKNOWLEDGMENTS**

The authors would like to thank Dr. C. Jackaman (Building 305, CHIRI Biomedical Science Precinct at Curtin University) for technical assistance. Immunofluorescent images shown in this article were generated as part of a project funded by the National Health and Medical Research Council Australia (APP1031330).

**REFERENCES**

1. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. The canals of hering and hepatic stem cells in humans. *Hepatology* (1999) 30(6):1425–33. doi:10.1002/hep.510306014
2. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ducts, and ductular reactions in human livers. *Hepatology* (2004) 39(6):1739–45. doi:10.1002/hep.20130
3. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. *Nat Genet* (2011) 43(1):34–41. doi:10.1038/ng.222
4. Espanol-Suner R, Carpenter R, Van Hul N, Legry V, Achouri Y, Cordi S, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. *Gastroenterology* (2012) 143(6):1564.e–75.e. doi:10.1053/j. gastro.2012.08.024
5. Viebahn CS, Tirsnit-Parker JE, Olynyk JK, Yeo GC. Evaluation of the "Cellscreen" system for proliferation studies on liver progenitor cells. *Eur J Cell Biol* (2006) 85(12):1265–74. doi:10.1016/j.ejcb.2006.08.006
6. Knight B, Tirnitz-Parker JE, Olynik JK. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology (2008) 135(3):396-79. doi:10.1053/j.gastro.2008.05.077
7. Brooiling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. *Hepatology* (2005) 41(4):906–15. doi:10.1002/hep.20645
8. Nguyen LN, Furuya MH, Wolfraim LA, Nguyen AP, Holdren MS, Campbell JS, et al. Transforming growth factor-beta differentially regulates oval cell and hepatic progenitor proliferation. *Hepatology* (2007) 45(1):31–41. doi:10.1002/hep.21466
9. Jung Y, Witak RP, Syn WK, Choi SS, Omenetti A, Premont R, et al. Signals from dying hepatocytes trigger growth of liver progenitors. *Gut* (2010) 59(5):655–65. doi:10.1136/gut.2009.194354
10. Grzelak CA, Martelotto LG, Siglekov ND, Patkanunnathan B, Aji F, Calabro SR, et al. The intranepithelial signalling niche of hedgehog is defined by primary cilium positive cells during chronic liver injury. *J Hepatol* (2014) 60(1):143–51. doi:10.1016/j.jhep.2013.09.012
11. Medracker I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun* (2013) 4:2823. doi:10.1038/ncomms3823
12. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of cell function and wound healing in a murine model of chronic liver injury. *J Clin Invest* (2010) 124(1):52–67. doi:10.1172/JCI39001
13. Ruddell RG, Knight B, Tirnitz-Parker JE, Akhurst R, Summerville L, Subramaniam VN, et al. Lymphotxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. *Hepatology* (2009) 49(1):227–39. doi:10.1002/hep.22597
14. Lowes KN, Brennan BA, Yeoh GC, Olynik JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. *Am J Pathol* (1999) 154(2):537–41. doi:10.1016/S0002-9440(10)5299-6
15. Sobaniec-Lotowska ME, Lotowska JM, Lebernsztejn DM. Ultrastructure of oval cells in children with chronic hepatitis B, with special emphasis on the stage of liver fibrosis: the first pediatric study. *World J Gastroenterol* (2007) 13(21):2981–22.
16. Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, et al. TWEAK induces liver progenitor cell proliferation. *J Clin Invest* (2005) 115(9):2330–40. doi:10.1172/JCI23486
17. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and canalicular lipids. *Gastroenterology* (2007) 135(6):1460–73. doi:10.1053/j.gastro.2007.04.057
18. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. *J Biol Chem* (1997) 272(11):32401–10. doi:10.1074/jbc.272.31.32401
19. Dwyer et al. Cellular cross-talk in chronic liver injury. *Frontiers in Immunology: Inflammation* (2014) 5(2):533–44. doi:10.3389/fimmu.2014.00267
20. Boulter L, Lu WY, Forbes SJ. Differentiation of progenitors in the liver: a matter of local choice. *J Clin Invest* (2013) 123(5):1867–73. doi:10.1172/JCI66026
21. Tirnitz-Parker JE, Olynik JK, Ramm GA. Role of TWEAK in co-regulating liver progenitor cell function and fibrogenic responses. *Hepatology* (2013). doi:10.1002/hep.26701
22. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. *J Biol Chem* (1997) 272(11):32401–10. doi:10.1074/jbc.272.31.32401
23. Wiley SR, Cassiano L, Loften T, Davis-Smith T, Winkles JA, Lindman V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. *Immunity* (2001) 15:587–46. doi:10.1016/S1074-7613(01)00252-1
24. Feng SL, Guo Y, Factor VM, Thorgerisson SS, Bell DW, Testa JR, et al. The Fln4 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepaticcellularomas. *Am J Pathol* (2000) 156(4):1233–61. doi:10.1016/S0002-9440(10)64996-6
25. Burkly LC, Michaelson JS, Hahn K, Jakubowski A, Zheng TS. TWEAKing tissue repair reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun* (2013) 4:1010. doi:10.1038/ncomms3823
26. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cyto- plasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and mediates nuclear factor-kappaB activation. *Cell Res* (2005) 15(2):344–62. doi:10.1038/cr.2008.0.20
27. Subrata LS, Olynyk JK, Yeoh GC, Quail EA, Abraham LJ. TNF expression in the tumor necrosis factor family member lymphotxin-beta is regulated by interleukin (IL)-6 and IL-1beta: transcriptional control mechanisms in oval cells and hepatoma cells. *Liver Int* (2005) 25(3):635–46. doi:10.1111/j.1478-3231.2005.01080.x
28. Subrata LS, Voos DC, Yeoh GC, Ugliati D, Quail EA, Abraham LJ. TNF-inducible expression of lymphotxin-beta in hepatic cells: an essential role for NF-kappaB and Erk transcription factors. *Cytokine* (2012) 60(2):498–504. doi:10.1016/j.cyto.2012.05.029
29. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB p105 processing and long lasting NF-kappaB activation. *J Biol Chem* (2003) 278(8):6506–15. doi:10.1074/jbc.M304266200
30. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fln4 cyto- plasmic tail binds tumor-necrosis-factor-receptor-associated factors 1, 2, 3 and mediates nuclear factor-kappaB activation. *Biochem J* (2003) 371(Pt 2):395–403. doi:10.1042/BJ20021730
31. Kuramitsu K, Sverdlov DY, Lin SH, Czamadia E, Burky L, Schuppam D, et al. Failure of fibroblastic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. *Am J Pathol* (2013) 183(1):182–94. doi:10.1016/j.ajpath.2013.03.018
32. Duffield JS, Forbes SJ, Constandinos CA, Clark S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. *J Clin Invest* (2005) 115(1):56–65. doi:10.1172/JCI22675
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 October 2013; accepted: 22 January 2014; published online: 13 February 2014.

Citation: Dwyer BJ, Olynyk JK, Ramm GA and Tirnitz-Parker JEE (2014) TWEAK and LTβ signaling during chronic liver disease. Front. Immunol. 5:39. doi:10.3389/fimmu.2014.00039

This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.

Copyright © 2014 Dwyer, Olynyk, Ramm and Tirnitz-Parker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.